EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial

Arturo Evangelista, Laura Galian-Gay iD, Andrea Guala, Gisela Teixido-Tura iD, Francisco Calvo-Iglesias iD, Teresa Sevilla iD, Javier Bermejo iD, Irene Méndez iD, Violeta Sánchez iD, Juan M Robledo Carmona iD, Josep M Alegret, Elena Ferrer-Sistach iD und 9 weitere

Circulation · 2024

DOI: 10.1161/circulationaha.123.067537 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2024. Verfasst von Arturo Evangelista und 20 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Cardiologia (A.E., L.G.-G., G.T.-T., A.R.-M., M.A.C., H.C.-C., I.F.-G., J.F.R.-P.), Hospital Universitari Vall d´Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Atorvastatin, Aortic Valve, Disease Progression, Calcinosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ascending aorta dilation and aortic valve degeneration are common complications in patients with bicuspid aortic valve. Several retrospective studies have suggested the benefit of statins in reducing these complications. This study aimed to determine whether atorvastatin treatment is effective in reducing the growth of aortic diameters in bicuspid aortic valve and if it slows the progression of valve calcification. METHODS: In a randomized clinical trial, 220 patients with bicuspid aortic valve (43 women; 46±13 years of age) were included and treated with either 20 mg of atorvastatin per day or placebo for 3 years. Inclusion criteria were ≥18 years of age, nonsevere valvular dysfunction, nonsevere valve calcification, and ascending aorta diameter ≤50 mm. Computed tomography and echocardiography studies were performed at baseline and after 3 years of treatment. RESULTS: During follow-up, 28 patients (12.7%) discontinued medical treatment (15 on atorvastatin and 13 taking placebo). Thus, 192 patients completed the 36 months of treatment. Low-density lipoprotein cholesterol levels decreased significantly in the atorvastatin group (median [interquartile range], −30 mg/dL [−51.65 to −1.75 mg/dL] versus 6 mg/dL [−4, 22.5 mg/dL]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinAortic ValveDisease ProgressionCalcinosisBicuspid Aortic Valve DiseaseHeart Valve DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsHumansFemaleMaleMiddle AgedAdultDilatation, PathologicFollow-Up StudiesDouble-Blind MethodTreatment OutcomeAortaAortic Valve DiseaseAortic Valve Stenosis

Stichwörter der Autor:innen

aortic valveaortic valve insufficiencyaortic valve stenosisatorvastatinbicuspid aortic valve diseasedilatation

Substanzen

AtorvastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Servei de Cardiologia (A.E., L.G.-G., G.T.-T., A.R.-M., M.A.C., H.C.-C., I.F.-G., J.F.R.-P.), Hospital Universitari Vall d´Hebron, Barcelona, Spain.
  • CIBER-CV (A.E., A.G., G.T.-T., T.S., J.B., I.M., V.S., J.M.R.-C., E.F., D.S., A.R.-M., J.F.R.-P.), Instituto de Salud Carlos III, Madrid, Spain.
  • Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain (A.E., L.G.-G., A.G., G.T.-T., A.R.-M., L.D.-S., A.S.-A., I.F.-G., J.F.R.-P.).
  • Hospital Alvaro Cunqueiro, Vigo, Spain (F.C.-I.).
  • Hospital Clínico Universitario de Valladolid, Spain (T.S.).
  • Hospital Gregorio Marañón, Madrid, Spain (J.B.).

ORCID-Profile: Laura Galian-Gay, Gisela Teixido-Tura, Francisco Calvo-Iglesias, Teresa Sevilla, Javier Bermejo, Irene Méndez, Violeta Sánchez, Juan M Robledo Carmona, Elena Ferrer-Sistach, Daniel Saura, Aroa Ruiz-Muñoz, Lydia Dux-Santoy, María Ángeles Carmona, Hug Cuellar-Calabria, Augusto Sao-Avilés

Zitieren

APA

Evangelista, A., Galian-Gay, L., Guala, A., Teixido-Tura, G., Calvo-Iglesias, F., Sevilla, T., Bermejo, J., Méndez, I., Sánchez, V., Robledo Carmona, J. M., Alegret, J. M., Ferrer-Sistach, E., Saura, D., Ruiz-Muñoz, A., Dux-Santoy, L., Carmona, M. Á., Huguet, M., Cuellar-Calabria, H., Sao-Avilés, A., …, & Rodríguez-Palomares, J. F. (2024). Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial. Circulation. https://doi.org/10.1161/circulationaha.123.067537

Vancouver

Evangelista A, Galian-Gay L, Guala A, Teixido-Tura G, Calvo-Iglesias F, Sevilla T, et al. Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial. Circulation. 2024. doi:10.1161/circulationaha.123.067537

BibTeX
@article{Evangelista2024,
  author = {Evangelista, Arturo and Galian-Gay, Laura and Guala, Andrea and Teixido-Tura, Gisela and Calvo-Iglesias, Francisco and Sevilla, Teresa and Bermejo, Javier and Méndez, Irene and Sánchez, Violeta and Robledo Carmona, Juan M and Alegret, Josep M and Ferrer-Sistach, Elena and Saura, Daniel and Ruiz-Muñoz, Aroa and Dux-Santoy, Lydia and Carmona, María Ángeles and Huguet, Marina and Cuellar-Calabria, Hug and Sao-Avilés, Augusto and Ferreira-González, Ignacio and Rodríguez-Palomares, Jose F},
  title = {Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.123.067537}
}
Kostenlos starten →